UNSPSC 51332705: Batelapine maleate

This classification denotes the maleate form of an antipsychotic agent with the molecular structure C16H20N6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, P71TE299SG chemically known as 11h-(1,2,4)triazolo(1,5-c)(1,3)benzodiazepine, 2-methyl-5-(4-methyl-1-piperazinyl)-, but more commonly known as batelapine, which bears US NIH Compound Identifier 60717. European Medicines Agency schedules Batelapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06110MIG.

UNSPSC 51332705 Batelapine maleate is a Commodity code that nominally covers a specific pharmaceutical active ingredient, but recent state and local procurement activity under this code does not reflect direct purchasing of batelapine maleate itself. Instead, the opportunities tagged to this code involve broader pharmaceutical and health-supply procurement: Seminole County, Florida is seeking naloxone and drug deactivation systems through an IFB; the Texas Health and Human Services Commission is conducting an RFI on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is soliciting manufacturers of generic multi-source pharmaceuticals and OTC products through an RFP. The mismatch between the code's nominal scope and the actual procurement activity suggests the code may be misapplied or that state and local systems are tagging pharmaceuticals broadly under this Commodity without granular product-level differentiation. State and local buyers using this code span county health departments, state health and human services agencies, and cooperative purchasing entities serving multiple jurisdictions.

Activity appears concentrated in Florida, Texas, and Minnesota. The Seminole County IFB (solicitation IFB60459723LAS, due July 26, 2023) requests 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The Texas HHS Commission RFI (HHS0017013, response due April 3, 2026) explores vendor capacity for direct-to-manufacturer prescription fulfillment without pharmacy benefit managers or group purchasing organizations. The MMCAP RFP (S1070000015802, due March 26, 2026) seeks generic pharmaceutical manufacturers willing to supply through authorized wholesalers to state and local facilities across participating states including Oregon, with evaluation weighted 75 percent on price competitiveness and 10 percent on fixed pricing, effective July 1, 2026. Given the disconnect between the code name and the solicitations it tags, prospects should verify whether this code reflects actual demand for batelapine maleate or represents a categorical filing error in state procurement systems.